Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide. Sorafenib (Sora) is used as a targeted therapy for HCC treatment. Mesenchymal stem cells (MSCs) are applied as a new approach to fight malignancies. Drug res...
Main Authors: | Saieh Hajighasemlou, Mohsen Nikbakht, Saeedreza Pakzad, Samad Muhammadnejad, Safoora Gharibzadeh, Milad Mirmoghtadaei, Fariba Zafari, Iman Seyhoun, Jafar Ai, Javad Verdi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Evidence-Based Complementary and Alternative Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/9602728 |
Similar Items
-
Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
by: Faezeh Hosseinzadeh, et al.
Published: (2018-09-01) -
Incapacitated Capicua in Sorafenib-Resistant HCC
by: Dingzi Yin, PhD, et al.
Published: (2020-01-01) -
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
by: Oronzo Brunetti, et al.
Published: (2019-10-01) -
Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
by: Xi He, et al.
Published: (2021-07-01) -
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
by: Ariel Ka-Man Chow, et al.
Published: (2013-01-01)